Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749021 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
A Phase 1 study of Retinal Pigment Epithelial Detachment, sponsored by Clement K. Chan.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT00749021: Completed Phase 1 study of Retinal Pigment Epithelial Detachment, sponsored by Clement K. Chan.
NCT00749021 is a Phase 1 study of Retinal Pigment Epithelial Detachment that has completed, run by Clement K. Chan. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00749021, a Phase 1 study of Retinal Pigment Epithelial Detachment, has completed, sponsored by Clement K. Chan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (3)
California
- Jules Stein Eye Institute - Los Angeles
- Southern California Desert Retina Consultants - Palm Desert
South Dakota
- Black Hills Regional Eye Institute - Rapid City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
What the finished NCT00749021 record still lists
NCT00749021 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).
The record links to 1 condition, with Retinal Pigment Epithelial Detachment appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00749021 reports a single indexed study location in California, South Dakota.
Frequently Asked Questions
What is clinical trial NCT00749021 about?
NCT00749021 is a clinical study titled "Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments". This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.
What is the current status of trial NCT00749021?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-09. Estimated completion is 2012-08.
What conditions does trial NCT00749021 study?
This clinical trial studies the following conditions: Retinal Pigment Epithelial Detachment.
What interventions are being tested in trial NCT00749021?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00749021?
This trial is sponsored by Clement K. Chan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00749021 being conducted?
This trial has 3 study locations across California, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00749021's enrollment target sits among peer trials
40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia